Ju‐Whei Lee - Concepedia

Author

Ju‐Whei Lee

Dana-Farber Cancer Institute ORCID

Also Known As

Ju-Whei Lee, Juwhei Lee, Ju‐Whei Lee, Stearns, Vered

Publications

674

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Northwestern University Wake Forest University University of Pennsylvania Brown University

About

Ju‐Whei Lee is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	60
2	Health Sciences	1	1	36
3	Public Health	1	1	24
4	Neurology	1	1	36
5	Pathology	1	1	24

Ju‐Whei Lee

Publications

176

Citations

H-Index

Page 1

	Year	Citations
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial Nathaniel S. O’Connell, Fengmin Zhao, Ju‐Whei Lee, Journal of Clinical Oncology	2023	43
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials Chezi Ganzel, Ju‐Whei Lee, Hugo F. Fernández, Blood Advances Neurological DisorderMixed-phenotype Acute LeukemiaClinical NeurologySpinal OncologyMyeloid Neoplasia	2021	36
ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). Shanthi Marur, Ju‐Whei Lee, Anthony J. Cmelak, Journal of Clinical Oncology Surgical OncologyPathologyTumor BiologyOral CancerCancer-associated Virus	2012	24
Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients Samilia Obeng‐Gyasi, Noah Graham, Shaji Kumar, Blood Cancer Journal	2022	24
Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial Alice P. Chen, Keith T. Flaherty, Peter J. O’Dwyer, JCO Precision Oncology	2020	20
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma John Devin Peipert, Fengmin Zhao, Ju‐Whei Lee, JAMA Network Open	2024	17
Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML Marlise R. Luskin, Ju‐Whei Lee, Hugo F. Fernández, Blood	2014	12

Page 1